Evolving Epidemiology and Burden of Skin Cancer {#Sec1}
===============================================

The Increasing Incidence of Skin Cancer {#Sec2}
---------------------------------------

### Overall Skin Cancer {#Sec3}

Skin cancer, including both malignant melanoma (MM) and non-melanoma skin cancer (NMSC), represents the most common malignancy in Caucasians \[[@CR1]--[@CR10]\]. The incidence of both MM and NMSC is on the rise, with an annual increase in MM of 0.6% among adults over 50 years \[[@CR11]\]. The estimated number of new cases of skin melanoma in 2016 is 76,380, which represents 4.5% of all new cancer cases \[[@CR12]\]. Deviations in reported incidence rates exist and are attributed to varying risk factors amongst different populations, as well as discrepancies in national registration systems. Furthermore, the incidence of melanoma may be even higher than indicated, as the National Cancer Registries has reported an underestimation of its incidence in certain countries \[[@CR13]\].

#### Melanoma {#Sec40}

The increased incidence of melanoma has not been accompanied by a corresponding increase in mortality rates \[[@CR12]\]. This has led to the question of whether there is a true melanoma epidemic, or if the increased incidence represents an epiphenomenon attributable to over-diagnosis resulting from intense screening and more biopsies.

The increased incidence of melanoma in the USA involves all thickness groups (American Joint Committee on Cancer tumor categories) and is independent of socio-economic status (a surrogate marker for access to care and screening), suggesting that increased screening and biopsy alone cannot account for the dramatic change observed \[[@CR14], [@CR15]\]. This finding is in agreement with the results reported by Shaikh et al., who showed that thickness increased in T3/T4 tumors and nodular melanoma \[[@CR16]\]. These observations together "suggest that the melanoma epidemic is real and not simply an artefact of increased detection pressure of earlier-stage T1/T2 lesions" \[[@CR16]\].

Conversely, there is evidence that over-diagnosis may have a part to play. Recent epidemiologic studies indicate that melanoma in situ, with an annual incidence of 9.5% \[[@CR12]\], occupies a disproportionately high percentage of the overall increase in MM incidence \[[@CR17]\]. From the dermatopathologic point of view, there are studies suggesting a current trend towards reclassification of prior non-malignant diagnoses as ΜΜ \[[@CR18]\]. Furthermore, in a population-based study correlating the number of skin biopsies and the incidence of MM, the investigators noted that there was a parallel increase during a 15-year period, suggesting that the MM epidemic may also be related to increased scrutiny and number of biopsies \[[@CR19]\].

#### Non-Melanoma Skin Cancer {#Sec41}

NMSC includes, amongst others, Bowen's disease, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). In Caucasians, the incidence of NMSC is higher (by as much as 18--20 times) than that of MM \[[@CR20]--[@CR22]\]. However, there are significant limitations to NMSC epidemiology, mainly attributed to marked geographic variations in incidence rates, as well as to exclusion of NMSC by large cancer registries due to low mortality rates. Even secondary analyses, whereby incidence data are extracted from administrative healthcare databases, are comparatively limited \[[@CR23]\].

NMSC carries a substantial economic burden \[[@CR24], [@CR25]\]. In Australia, it is the most costly cancer, accounting for expenditure of AUS\$511 million in 2010 \[[@CR24]\]. In the USA, it has been estimated that total annual NMSC-related expenditure is US\$650 million, with Medicare costs 6--7 times greater than those for treating melanoma \[[@CR26]\].

Reasons for Increased Incidence of Skin Cancer {#Sec6}
----------------------------------------------

The observed increases in skin cancer rates are associated with several factors, including the transition toward significantly older populations that are associated with a higher risk of NMSC \[[@CR27]\]. However, research has also revealed the important role of increased occupational and recreational UV light exposure \[[@CR22], [@CR28]\]. For example, women \<40 years exhibited a constant linear increase in BCC incidence rates of 6.3% between 1973 and 2009 \[[@CR29]\], and studies have shown that indoor tanning is associated with a significantly increased risk of BCC and SCC, with a higher risk with use in early life (\<25 years) \[[@CR30]\].

Diagnostic and Therapeutic Approaches to Skin Cancer: Challenging Clinical Cases {#Sec7}
================================================================================

Skin Cancer Diagnosis {#Sec8}
---------------------

A diagnosis of skin cancer needs consideration of alternative diagnoses. Concerning actinic keratosis, benign conditions include seborrheic keratosis, verruca vulgaris, actinic porokeratosis, O'Brien's actinic granuloma, eczema, lentigo solaris, lichen planus, or psoriasis (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}), whereas malignant conditions include SCC, Bowen's disease, BCC, lentigo maligna, keratoacanthoma, or extramammary Paget's disease.Fig. 1Case studies: 80-year-old woman presenting with field cancerization, and 45-year-old woman presenting with lupus erythematodes (forehead and cheek shown) Fig. 2Case study: lichen planus complicating diagnosis in a 78-year-old man with actinic keratosis on his hand Fig. 3Case study: psoriasis complicating diagnosis in a 47-year-old man with actinic keratosis on his hand

Clinicians should ideally perform total body skin examination (see Fig. [4](#Fig4){ref-type="fig"} as an example case of actinic keratosis appearing on the back of the hand, as is often overlooked), at least for high-risk individuals \[[@CR31], [@CR32]\]. The use of non-invasive optical technologies, such as optical coherence tomography (non-invasive imaging test of the retina using light waves) or dermatoscopy (imaging of the skin, allowing statements concerning thickening of layers, epidermal organization, and borders of a lesion---in the case of actinic keratosis, the typical honeycomb pattern may be observed), may be helpful to improve diagnostic accuracy in some skin cancers \[[@CR33]--[@CR37]\] (the case presented in Fig. [5](#Fig5){ref-type="fig"} may have benefitted from such technologies, for example). Photodynamic visualization (fluorescent visualization of skin cancerization extension after preparation with 5-aminolaevulinic acid and subjection to photodynamic therapy \[light exposure\]) might also be beneficial for identification of actinic keratosis, with histologic confirmation also being necessary in cases in which invasive skin cancer is suspected \[[@CR38]\].Fig. 4Case study: cheilitis actinica versus actinic keratosis (mouth and cheek shown) Fig. 5Case study: 89-year-old woman presenting with multiple comorbidities (leg shown)

Treatment Challenges {#Sec9}
--------------------

Treatment strategies for skin cancers require careful consideration, and there are many challenges to overcome. However, with increasing treatment choices, in terms of both therapy combinations and sequences, we can achieve better outcomes for patients with fewer recurrences and longer treatment-free periods.

Field Cancerization and Non-Melanoma Skin Cancer {#Sec10}
------------------------------------------------

Field cancerization of the skin, by which large areas are affected by carcinogenic alternations, presents various therapeutic challenges (Fig. [6](#Fig6){ref-type="fig"}). Owing to the difficulty in determining which actinic keratosis lesions may progress to invasive SCC, European guidelines recommend that all lesions, or the affected field, are treated \[[@CR39]\]. For a patient with actinic keratosis, there are three evolutionary possibilities: spontaneous clearing; persistence; or progression to invasive SCC \[[@CR40]\]. Approximately 60--65% of primary SCCs are believed to have arisen from lesions previously diagnosed clinically as actinic keratosis \[[@CR41], [@CR42]\], and the rate at which a specific lesion may become SCC is estimated to be a fraction of a percent over the course of a year \[[@CR43]\]. Even when actinic keratosis lesions are classified according to their clinical appearance, there is little correlation with their histologic classification, thereby reinforcing the need to treat all actinic keratosis lesions and field cancerization \[[@CR44]\] (see "Cyclooxygenase in Cancer Prevention and Treatments for Actinic Keratosis", by Gareth Thomas and Colin Morton, published in this Supplement, for further details on actinic keratosis treatment). While long-term efficacy and tolerance of treatments are key considerations for clinicians, comorbidities may impact treatment success.Fig. 6Case study: field cancerization in an 80-year-old patient (head and shoulder/neck shown)

The broad actinic keratosis spectrum characterized by age, localization, medication, co-dermatoses, and exogenous factors (Figs. [1](#Fig1){ref-type="fig"}, [5](#Fig5){ref-type="fig"}) requires an individualized treatment approach for each patient. Figures [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"} and [8](#Fig8){ref-type="fig"} show examples of clinical cases. Patients who have received a kidney transplant represent a particularly challenging population. Skin tumors are a major problem in these patients, and key challenges for the clinician include treatment of the whole integument, sequential therapies, and achievement of long-term success when the patient is immunosuppressed (where inflammatory and immunomodulatory approaches are restricted). Figure [7](#Fig7){ref-type="fig"} shows an example of a transplant patient in whom there was a suspicion of actinic keratoses in an extended field, with treatment choices being operative or destructive.Fig. 7Case study: Treatment of a patient who had received a kidney transplant (leg shown) Fig. 8Case study: 85-year-old woman with multiple basal cell carcinomas (forehead shown)

Many more therapeutic options are available for non-immunosuppressed patients. However, there is still limited availability of some medications as they are not approved for all NMSC types and localizations (Table [1](#Tab1){ref-type="table"}). Furthermore, when extensive field cancerization encompassing the whole integument is evident, treatment must occur over a very large area of affected skin.Table 1Recommended topical treatments for actinic keratosisDrugEMA approval dateApproved for localizationArea5% 5-FU^a^ \[[@CR92]\]1998All localizations500 cm^2^5-FU 0.5% with 10% salicylic acid^b^ \[[@CR93]\]2011All localizations25 cm^2^ (maximum of 10 lesions)3% diclofenac with 2.5% hyaluronic acid^b^ \[[@CR94]\]2000All localizationsMaximum of 8 g/day5% imiquimod^a^ \[[@CR95]\]1998Head25 cm^2^3.75% imiquimod^a^ \[[@CR96]\]2012Head25 cm^2^0.05% ingenol mebutate^c^ \[[@CR97]\]2012Body, extremities25 cm^2^0.015% ingenol mebutate^c^ \[[@CR98]\]2012Head25 cm^2^Please refer to your local prescribing information^a^MEDA (<http://www.meda.co.za/>)^b^Almirall (<http://www.almirall.com/en/>)^c^LEO (<http://www.leo-pharma.co.uk/>)

Basal Cell Carcinoma {#Sec11}
--------------------

Though the majority of patients with BCC have a good prognosis, some patients develop a more complex, advanced disease with relatively few treatment options; indeed, no formal treatment algorithms are available. However, the recent development of hedgehog signaling pathway inhibitors, such as vismodegib, has been significant, providing an effective treatment option for some patients. In particular, vismodegib treatment may be appropriate if the tumor is considered inoperable and radiation therapy is declined; complete remission is achieved in 21% of locally advanced BCC \[[@CR45]\], even in those infiltrating adjacent muscle and bone structures. Many more cases with partial remission and shrinking tumors may be considered for operation (Fig. [8](#Fig8){ref-type="fig"}).

Malignant Melanoma Stage IV {#Sec12}
---------------------------

Treatment approaches for melanoma encompass two main strategies: targeted therapies (e.g., BRAF- and MEK-inhibitors); and immunotherapies (e.g., anti-CTLA-4 and anti-PD-1).

The combination of BRAF- and MEK-inhibitors is well established in patients with tumors harboring the BRAF mutation, primarily owing to the development of tumor resistance with BRAF-inhibitor monotherapy \[[@CR46]\]. Although this combination represents an effective option with an acceptable toxicity profile \[[@CR47]\], questions still remain as to whether sequential or cyclic application of BRAF- and MEK-inhibitors would be more beneficial, and whether immunotherapies may represent equally useful alternatives \[[@CR48]\].

With regard to immunotherapies, anti-PD-1 monotherapy may be preferable to anti-CLTA-4 monotherapy \[[@CR49]\]: combining anti-PD-1 and anti-CTLA-4 therapies may increase response and remission rates. However, this may be at the risk of higher toxicity (with predominantly gastrointestinal, hepatic, and cutaneous adverse events) \[[@CR50]\] and therefore would be most appropriate in patients with progressive disease or lower PD-L1 expression. Further studies on sequential/cyclic combinations of these immunotherapies with consideration of immunologically relevant parameters (e.g., PD-L1 expression levels, BRAF/NRAS/cKIT mutation analysis), tumor typing and staging, and patient characteristics (e.g., age, comorbidities, treatment history) are ongoing \[[@CR48]\].

The Sun: Friend or Foe? {#Sec13}
=======================

The Impact of Sunlight Exposure on Health {#Sec14}
-----------------------------------------

The impact of sunlight exposure on health is subject to debate---here, we present our views on the available evidence. Several epidemiologic studies have provided evidence for the beneficial effect of sun exposure on overall health status. All-cause mortality (death due to any cause) was inversely correlated with increased sun exposure in several studies, with a particular reduction in cardiovascular mortality. A nationwide Danish case--control study showed that having a diagnosis of skin cancer, a marker for sun exposure, was associated with a lower incidence of myocardial infarction, fewer hip fractures in those below the age of 90 years, and fewer deaths from any cause \[[@CR51]\]. Similarly, among Swedish women, habits indicating avoidance of sun exposure were a risk factor for all-cause mortality; the mortality rate among such 'avoiders' was approximately two-fold higher compared with the highest sun exposure group \[[@CR52]\]. It is possible that severely restricting sun exposure, particularly at locations with low solar intensity, might in fact have a negative effect on health \[[@CR52]\].

In addition, studies have shown that blood pressure and the incidence of ischemic heart disease correlate with the latitude of a person's country of residence \[[@CR53], [@CR54]\]. It is also known that blood pressure is lower during summer compared with winter \[[@CR55]\]. This is of great significance as high blood pressure is the leading cause of disease and premature death in the world \[[@CR56], [@CR57]\].

Meta-analyses of several studies indicate that serum vitamin D levels are inversely correlated with blood pressure and the incidence of cardiovascular disease, diabetes, and hypertension \[[@CR58], [@CR59]\]. Furthermore, observational studies indicate that the risk of death from any cause is correlated with circulating 25-hydroxyvitamin D \[[@CR60]\]. However, extensive studies, comprising meta-analyses of several clinical trials, have conclusively shown that oral vitamin D supplementation has no effect on blood pressure, ischemic heart disease, or stroke \[[@CR58], [@CR61]\], although vitamin D3 supplementation may reduce all-cause mortality \[[@CR60]\]. Although vitamin D may account for some of the beneficial effects observed with sunlight exposure, it may be considered a marker of the person's occupational or recreational sun exposure.

### Nitric Oxide and the Skin as a Mechanism Behind the Positive Effects of Sunlight {#Sec15}

It has been proposed that many of the documented beneficial effects of exposure to sunlight, particularly those related to cardiovascular health, involve mechanisms unrelated to melatonin, vitamin D, and exposure to UVB \[[@CR62]\]. Recent studies suggest that stores of nitric oxide (NO)-related species in the skin may be particularly important in this respect. Both the skin and the dermal vasculature contain biologically significant stores of bound NO species \[[@CR63]\]. Upon exposure of the skin to UVA, photodecomposition of these NO stores takes place and NO species are released into the circulation, resulting in arterial vasodilation, with cardioprotective and antihypertensive effects \[[@CR62], [@CR64]\]. This mechanism has also been shown to suppress the development of diabetes and metabolic syndrome in a mouse model \[[@CR65]\]. Long-term suberythemal and erythemal UV light significantly suppressed weight gain, glucose intolerance, and insulin resistance in mice fed a high-fat diet, an effect that was not reproduced by vitamin D supplementation. Importantly, skin induction of NO reproduced many of the effects of UV radiation \[[@CR65]\].

What Should a Dermatologist Know About HPV? {#Sec16}
===========================================

There are several key areas in which knowledge of HPV natural history and vaccination status is important for dermatologists. Table [2](#Tab2){ref-type="table"} provides examples of common questions, along with evidence-based responses for each question.Table 2What should the dermatologist know about HPV? Key questions and answersQuestionAnswerDoes every patient develop genital warts after HPV infection?Even though HPV infection is very common, very few patients will develop genital warts after infectionHow long can HPV infections last?Up to 90% of HPV infections will clear within 2 yearsIs a patient with subclinical infection contagious?Yes, but we should distinguish between subclinical and latent infections (we know very little about latent infections). subclinical infections do exist and can last for years, but they are probably only contagious when there is viral replication and sheddingIs the patient no longer infectious once genital warts have been treated?Patients can be infectious even after removal/treatment of genital wartsIs there a rationale for treating subclinical HPV infections?No, what is important is the lesions, not the infection itselfWhat should be the advice for patients who have been treated for genital warts, but who may still have subclinical infection?The important thing to focus on is the lesions; screening for early lesions, and subsequent treatment\
Although there is no formal recommendation, HPV vaccination is advised among patients with a history of HPV-related lesionsWhat advice should patients receive for their sexual partners concerning infection?The important thing to focus on is the lesions; screening for early lesions, and subsequent treatment\
Although there is no formal recommendation, HPV vaccination is advised among patients with a history of HPV-related lesionsIs there any risk of HPV-related cancer in male patients?Only patients who do not resolve HPV infections are at a higher risk of HPV persistence and subsequent HPV-related diseases, including pre-cancer and cancerDo HPV vaccines protect against other HPV genotypes that may cause genital warts?Yes, they protect against HPV types 6 and 11 that cause 90% of genital warts and recurrent respiratory papillomatosisConsidering the cost of the vaccine, is there enough evidence for vaccination of already infected patients? And for their sexual partners?The current cost of HPV vaccines in national immunization programs has been reduced threefold\
Yes, the vaccine will not cure current active infections but will block new infections as well as auto-inoculated virionsIs there a rationale for HPV vaccination in young males?Yes, very strong, and threefold:\
1. To reduce transmission and circulation in the population\
2. To protect themselves (male burden is now considerable)\
3. For gender equality

Human Papillomavirus and Cancer {#Sec17}
-------------------------------

More than 150 human papillomavirus (HPV) types have so far been identified. HPV falls into five genera, with the Alpha and Beta/Gamma genera representing the largest groups \[[@CR66]\]. Mucosal HPV types from the Alpha genus are the ones associated with neoplastic disease and the most common viral infections of the reproductive tract; the World Health Organization acknowledges that most sexually active men and women will be infected at some point in their lives \[[@CR67]\]. Twelve Alpha HPVs are classified as carcinogenic to humans and fifteen as probably/possibly carcinogenic \[[@CR68]\]. Two HPVs, HPV 16 and 18, stand out for their carcinogenicity and contribute to approximately 70% of all HPV-related cancers worldwide \[[@CR69]--[@CR74]\]. Although most infections resolve spontaneously and the majority of women with infection do not develop cancer, a small proportion of HPV infections will persist and progress to pre-cancer and cancer \[[@CR75]\]. Protective risk factors that reduce the risk of HPV infection and subsequent cancer include consistent condom use \[[@CR76]\], male circumcision \[[@CR77]\], and use of an intrauterine device \[[@CR78]\].

The impact of the estimated contribution of HPV to cancer from an epidemiologic point of view is larger than previously thought. Indeed, HPV infection can be considered a pandemic disease for several reasons \[[@CR79]\]. Firstly, it is universal and widespread, occurring on all continents, in both women and men, among young people and adults, and across most races and socioeconomic groups. Secondly, it is extensive, as it causes a variety of related diseases, both pre-cancerous and cancerous, involving a wide range of anatomic sites. Finally, the epidemiology of HPV is dynamic, as opposed to stable, with increasing rates of infection and disease.

The Role of HPV in Skin Cancer {#Sec18}
------------------------------

Some studies suggest that a particular genus, the β HPVs, may play a role in the pathogenesis of NMSC \[[@CR80]\], though this role has not been well studied. However, the association of β HPV infection with NMSC in patients with a very rare, genetically determined condition, epidermodysplasia verruciformis, has been well established \[[@CR81]\]. In stark contrast to α HPV-associated cancers (such as cervical cancer, as discussed above), the presence of β-HPV DNA does not appear to be essential for the maintenance of the malignant phenotype \[[@CR82]\].

Prevention Through Vaccination Strategies {#Sec19}
-----------------------------------------

Three HPV vaccines are commercially available including a bivalent form against HPV types 16 and 18, a quadrivalent form against HPV types 6, 11, 16 and 18, and a 9-valent form against types 6, 11, 16, 18, 31, 33, 45, 52 and 58 \[[@CR83]\]. Persistent infection with high-risk HPV types 16 and 18 is responsible for the majority of cervical cancer worldwide, whereas low-risk types 6 and 11 are responsible for most genital warts \[[@CR84]\]. The vaccines are highly efficacious, immunogenic and safe in the prevention of pre- and neoplastic cervical-, vulvar-, vaginal- or anal-related disease in women \[[@CR85]--[@CR87]\]. The quadrivalent HPV vaccine has been shown to be effective against genital warts \[[@CR88], [@CR89]\] and anal precancerous lesions \[[@CR90]\]. As well as being associated with wart formation, cutaneous papillomaviruses can lead to the development of NMSC, but further research with HPV vaccines is needed to assess their efficacy in preventing NMSC.

Data from multiple countries have shown a clear impact in the reduction of HPV infections and related conditions within a few years of vaccine introduction \[[@CR91]\], and pediatricians, gynecologists, primary healthcare professionals, clinicians, and public health officials, as well as dermatologists, have all played a key role in achieving this wide vaccination coverage.
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